Kestra Medical Technologies, Ltd.
KMTS Nasdaq Surgical & Medical Instruments & Apparatus Financials FY2024–FY2026
Revenue
Total sales reported in the income statement.
$95.1M
59.0%
vs prior year
Operating margin
Operating income as a share of revenue.
−141.6%
36.2 pts
Net income
Profit after all expenses, interest and tax.
−$132M
Free cash flow
Cash from operations minus capital spending.
−$117M
Return on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
−100.5%
842.8 pts
Market cap
Last close times the latest diluted share count, so it is approximate.
—
P/E
Last close divided by diluted earnings per share over the last four quarters.
—
On −$2.68 EPS (TTM)
What Kestra Medical Technologies, Ltd. does
No business description yet.
- Legal name
- KESTRA MEDICAL TECHNOLOGIES, LTD.
- Fiscal year ends
- April 30, 2026
- Latest annual report
- 10-K · Jul 14, 2026
- Accession · CIK
- 0001193125-26-303397
0001877184
Revenue and margins
Kestra Medical Technologies, Ltd. had $95.1M of revenue in fiscal 2026, up 59.0% on the year before.
FY24
Revenue $27.8M
FY25
Revenue $59.8M
FY26
Revenue $95.1M
Q1 '25
Revenue $12.8M
Q2 '25
Revenue $14.7M
Q3 '25
Revenue $15.1M
Q4 '25
Revenue $17.2M
Q1 '26
Revenue $19.4M
Q2 '26
Revenue $22.6M
Q3 '26
Revenue $24.6M
Q4 '26
Revenue $28.6M
Q1 '27
Revenue $31.0M
FY24
Gross 1.3%
Operating −305.8%
Net −338.4%
FCF −303.7%
FY25
Gross 40.5%
Operating −177.8%
Net −190.3%
FCF −168.1%
FY26
Gross 51.4%
Operating −141.6%
Net −138.4%
FCF −122.6%
Gross
Operating
Net
FCF
Q1 '25
Gross 32.9%
Operating −144.2%
Net −155.6%
FCF −192.0%
Q2 '25
Gross 39.6%
Operating −130.1%
Net −138.5%
FCF −153.0%
Q3 '25
Gross 43.4%
Operating −136.5%
Net −142.5%
FCF −146.2%
Q4 '25
Gross 44.3%
Operating −279.8%
Net −302.1%
FCF −182.5%
Q1 '26
Gross 45.7%
Operating −149.1%
Net −133.3%
FCF −177.8%
Q2 '26
Gross 50.6%
Operating −140.7%
Net −145.3%
FCF −113.5%
Q3 '26
Gross 52.6%
Operating −141.6%
Net −139.2%
FCF −114.7%
Q4 '26
Gross 54.8%
Operating −137.4%
Net −135.6%
FCF −99.1%
Q1 '27
Gross 56.5%
Operating −121.6%
Net −142.3%
FCF −131.2%
Gross
Operating
Net
FCF
Net income and earnings per share
Loss periods are shown in red.
FY24
Net income −$94.1M
FY25
Net income −$114M
FY26
Net income −$132M
Q1 '25
Net income −$19.9M
Q2 '25
Net income −$20.4M
Q3 '25
Net income −$21.5M
Q4 '25
Net income −$52.1M
Q1 '26
Net income −$25.8M
Q2 '26
Net income −$32.8M
Q3 '26
Net income −$34.2M
Q4 '26
Net income −$38.8M
Q1 '27
Net income −$44.1M
FY24
Diluted EPS −$5.07
FY25
Diluted EPS −$5.13
FY26
Diluted EPS −$2.43
Q1 '25
Diluted EPS −$1.12
Q2 '25
Diluted EPS −$1.19
Q3 '25
Diluted EPS −$1.25
Q4 '25
Diluted EPS −$1.57
Q1 '26
Diluted EPS −$0.50
Q2 '26
Diluted EPS −$0.64
Q3 '26
Diluted EPS −$0.61
Q4 '26
Diluted EPS −$0.68
Q1 '27
Diluted EPS −$0.75
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
FY24
Return on capital —
Return on equity —
Return on assets −204.8%
FY25
Return on capital −943.3%
Return on equity —
Return on assets −66.6%
FY26
Return on capital −100.5%
Return on equity −56.6%
Return on assets −40.2%
Return on capital
Return on equity
Return on assets
Cash flow
Free cash flow was −$117M in fiscal 2026, −122.6% of revenue. Cash from operations minus capital spending.
FY24
Free cash flow −$84.5M
FY25
Free cash flow −$101M
FY26
Free cash flow −$117M
Q1 '25
Free cash flow −$24.5M
Q2 '25
Free cash flow −$22.5M
Q3 '25
Free cash flow −$22.1M
Q4 '25
Free cash flow −$31.4M
Q1 '26
Free cash flow −$34.4M
Q2 '26
Free cash flow −$25.6M
Q3 '26
Free cash flow −$28.2M
Q4 '26
Free cash flow −$28.4M
Q1 '27
Free cash flow −$40.6M
FY24
Cash from operations −$72.2M
Capital spending $12.2M
FY25
Cash from operations −$77.6M
Capital spending $22.9M
FY26
Cash from operations −$81.7M
Capital spending $34.9M
Cash from operations
Capital spending
Q1 '25
Cash from operations −$17.5M
Capital spending $7.0M
Q2 '25
Cash from operations −$18.1M
Capital spending $4.4M
Q3 '25
Cash from operations −$18.0M
Capital spending $4.1M
Q4 '25
Cash from operations −$24.1M
Capital spending $7.4M
Q1 '26
Cash from operations −$26.3M
Capital spending $8.2M
Q2 '26
Cash from operations −$18.3M
Capital spending $7.3M
Q3 '26
Cash from operations −$18.4M
Capital spending $9.8M
Q4 '26
Cash from operations −$18.7M
Capital spending $9.7M
Q1 '27
Cash from operations −$32.3M
Capital spending $8.3M
Cash from operations
Capital spending
Dividends, buybacks and share count
Kestra Medical Technologies, Ltd. returned — to shareholders in fiscal 2026. The diluted share count rose 120.4%.
FY24
Dividends —
Buybacks —
FY25
Dividends —
Buybacks —
FY26
Dividends —
Buybacks —
Dividends
Buybacks
FY24
Diluted shares 0.02B
FY25
Diluted shares 0.02B
FY26
Diluted shares 0.05B
Balance sheet
Cash, debt and the ratios that show how comfortably Kestra Medical Technologies, Ltd. can carry it.
FY24
Cash $8.2M
Debt $42.5M
FY25
Cash $238M
Debt $41.1M
FY26
Cash $196M
Debt $42.6M
Cash
Debt
| Fiscal year end | FY24 | FY25 | FY26 |
|---|---|---|---|
| Cash and short-term investments | $8.2M | $238M | $196M |
| Debt incl. finance leases | $42.5M | $41.1M | $42.6M |
| Debt / equity | — | 0.2x | 0.2x |
| Interest coverage | −13.7x | −13.8x | −17.9x |
| Current ratio | 0.5x | 6.7x | 4.4x |
| Quick ratio | 0.5x | 6.7x | 4.4x |
| Total assets | $45.9M | $296M | $358M |
| Total liabilities | $78.2M | $90.3M | $98.8M |
| Shareholders' equity | −$209M | $205M | $260M |
| Net debt (− = net cash) | $34.3M | −$196M | −$154M |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY24 | FY25 | FY26 |
|---|---|---|---|
| Net income is positive | ✕ | ✕ | ✕ |
| Cash from operations is positive | ✕ | ✕ | ✕ |
| Return on assets rose | — | ✓ | ✓ |
| Cash from operations exceeds net income | ✓ | ✓ | ✓ |
| Debt fell relative to assets | — | ✓ | ✓ |
| Current ratio rose | — | ✓ | ✕ |
| Share count didn't rise | — | ✕ | ✕ |
| Gross margin rose | — | ✓ | ✓ |
| Revenue rose relative to assets | — | ✕ | ✓ |
| F-score | — / 3 | 5 / 9 | 5 / 9 |
| Accruals ratio | −47.6% | −21.2% | −15.3% |
| Altman Z'' | −46.67 | −0.94 | −2.55 |
3 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY24 | FY25 | FY26 |
|---|---|---|---|
| Income statement | |||
| Revenue | $27.8M | $59.8M | $95.1M |
| Gross profit | $0.4M | $24.2M | $48.9M |
| Research and development | $15.5M | $15.7M | $19.5M |
| Operating income | −$85.1M | −$106M | −$135M |
| Interest expense | $6.2M | $7.7M | $7.5M |
| Pretax income | −$94.1M | −$114M | −$131M |
| Income tax | $0.0M | $0.1M | $0.3M |
| Net income | −$94.1M | −$114M | −$132M |
| Net income to common | −$101M | −$126M | −$132M |
| Diluted EPS | −$5.07 | −$5.13 | −$2.43 |
| Diluted shares | 0.02B | 0.02B | 0.05B |
| Cash flow | |||
| Cash from operations | −$72.2M | −$77.6M | −$81.7M |
| Capital expenditure | $12.2M | $22.9M | $34.9M |
| Free cash flow | −$84.5M | −$101M | −$117M |
| Depreciation and amortization | $11.6M | $8.0M | $8.7M |
| Stock-based compensation | $1.5M | $24.3M | $33.6M |
| Balance sheet | |||
| Cash and short-term investments | $8.2M | $238M | $196M |
| Total debt | $42.5M | $41.1M | $42.6M |
| Current assets | $14.9M | $255M | $222M |
| Current liabilities | $33.0M | $38.0M | $50.4M |
| Property and equipment, net | $26.1M | $34.8M | $59.1M |
| Total assets | $45.9M | $296M | $358M |
| Total liabilities | $78.2M | $90.3M | $98.8M |
| Shareholders' equity | −$209M | $205M | $260M |
| Margins | |||
| Gross margin | 1.3% | 40.5% | 51.4% |
| Operating margin | −305.8% | −177.8% | −141.6% |
| EBITDA margin | −264.3% | −164.5% | −132.5% |
| Net margin | −338.4% | −190.3% | −138.4% |
| FCF margin | −303.7% | −168.1% | −122.6% |
| Returns | |||
| Return on capital | — | −943.3% | −100.5% |
| Return on capital employed | −655.4% | −41.3% | −43.7% |
| Return on equity | — | — | −56.6% |
| Return on assets | −204.8% | −66.6% | −40.2% |
| Return on tangible equity | — | −61.4% | −50.7% |
| Growth | |||
| Revenue growth | — | 115.1% | 59.0% |
| Share count change | — | 23.6% | 120.4% |
| Financial health | |||
| Debt / equity | — | 0.2x | 0.2x |
| Interest coverage | −13.7x | −13.8x | −17.9x |
| Current ratio | 0.5x | 6.7x | 4.4x |
| Quick ratio | 0.5x | 6.7x | 4.4x |
| Capital allocation | |||
| Capex / revenue | 44.0% | 38.3% | 36.7% |
| Stock comp / revenue | 5.3% | 40.6% | 35.4% |
| Quality scores | |||
| Piotroski F-score | — | 5.0 | 5.0 |
| Altman Z'' | −46.7 | −0.9 | −2.5 |
| Accruals ratio | −47.6% | −21.2% | −15.3% |
Source: SEC EDGAR XBRL filings (CIK 0001877184). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.